Pharmafile Logo
Pharmafocus logo
Advanced Search

pharma

Showing 15 posts of 2914 posts found.

novo_nordisk_flag

Novo’s semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD

January 17, 2020
Medical Communications, Sales and Marketing FDA, Novo Nordisk, Ozempic, cardiovascular disease, diabetes, pharma

Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 (GLP-1) analogue injection Ozempic (once-weekly …

News
abbvie_0

AbbVie’s Skyrizi outpaces Novartis’ Cosentyx in plaque psoriasis skin clearance

January 16, 2020
Research and Development AbbVie, Cosentyx, Novartis, Skyrizi, pharma, psoriasis

AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque …

News

NICE shoots down Keytruda in head and neck cancer over data concerns

January 16, 2020
Sales and Marketing Cancer, NHS, NICE, UK, keytruda, pharma

It has been revealed that NICE has chosen to reject MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) for routine use on the …

News
40542895134_9f6048fa40_b

FDA panel votes against Nektar opioid painkiller

January 15, 2020
Research and Development Bernie Opioids, Big Pharma, Trump opioids, opioid, opioid crisis, opioids, pharma

FDA unanimously voted against Nektar Therapeutics opioid pankiller (NKTR-181) for chronic lower back pain, prompting the company to withdraw its …

News

Pfizer’s Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer

January 15, 2020
Research and Development Cancer Drugs Fund, NICE, Pfizer, ibrance, pharma

NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s …

News
shutterstock_512649

MorphoSys and Incyte forge potential $1.1bn partnership to develop B cell malignancy drug candidate

January 14, 2020
Manufacturing and Production, Sales and Marketing Incyte, morphosys, pharma, tafasitamab

MorphoSys and Incyte have joined together in a partnership to develop and commercialise the latter’s anti-CD19 antibody tafasitamab as a …

News
biogen_austria_238

Biogen picks up Pfizer’s Phase 1 therapy for Alzheimer’s symptoms in potential $700m deal

January 14, 2020
Manufacturing and Production, Sales and Marketing Alzheimer's, Biogen, Pfizer, pharma

Biogen has entered into an agreement with Pfizer to acquire the latter’s Phase 1 candidate PF-05251749 in order to develop …

News
jp-kress_mor

Working Life Interview: Jean-Paul Kress, CEO of MorphoSys

January 13, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Working Life, feature, morphosys, pharma

With a medical doctorate as well as degrees in pharmacology and immunology under your belt, was your path always to …

Feature
shutterstock_273326141

Eli Lilly to boost immunology portfolio with $1.1bn Dermira acquisition

January 13, 2020
Sales and Marketing Dermira, Eli Lilly, pharma

Eli Lilly has announced it has entered into an agreement to acquire Dermira, a biopharmaceutical firm focused on the development …

News

Sanofi secures expanded European approval for Toujeo in type 1 diabetes

January 10, 2020
Medical Communications, Sales and Marketing EU, Sanofi, pharma, toujeo

Sanofi has revealed that the European Commission has expanded the existing label for Toujeo (insulin glargine 300 units/mL) to include …

News
48612088061_36c0f87278_b

Idorsia reveals it is working with Neurocrine on new epilepsy drug deal

January 10, 2020
Medical Communications FDA, Idorsia, Neurocrine, drugs, epilepsy, pharma

Idorsia revealed its 2019 deal for its investigational epilepsy medicine was with Neurocrine Biosciences, and it is potentially worth more …

News

US approval for Blueprint Medicines’ gastrointestinal stromal tumour therapy

January 10, 2020
Medical Communications, Sales and Marketing Ayvakit, Blueprint Medicines, Cancer, pharma

The FDA has moved to authorise Blueprint Medicines’ kinase inhibitor Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal …

News
merck-keytruda

MSD’s Keytruda chalks up bladder cancer approval in the US

January 9, 2020
Sales and Marketing Cancer, MSD, bladder cancer, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has added another US approval to its repertoire with the news that FDA has awarded …

News
nmpa_logo

China approves first homegrown HPV vaccine

January 8, 2020
Research and Development, Sales and Marketing China, HPV, NMPA, pharma, vaccines

Female patients in China between the ages of nine and 45 will have access to the country’s first domestically-produced vaccine …

News
shutterstock

Apellis therapy outflanks Alexion’s Soliris in head-to-head paroxysmal nocturnal haemoglobinuria

January 8, 2020
Research and Development Alexion, Appelis, pegcetacoplan, pharma, soliris

Apellis Pharmaceuticals has revealed new Phase 3 demonstrating that its targeted C3 inhibitor pegcetacoplan met its primary endpoint and outclassed …

News
The Gateway to Local Adoption Series

Latest content

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026

Accord Healthcare appoints Paul Burden as Associate Vice President and Country Head UK

February 2, 2026

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026